Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AMP945 |
| Synonyms | |
| Therapy Description |
AMP945 is a selective inhibitor of focal adhesion kinase (Cancer Res 2022;82(12_Suppl):Abstract nr CT511). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AMP945 | AMP 945|AMP-945|Narmafotinib | FAK inhibitor 16 | AMP945 is a selective inhibitor of focal adhesion kinase (Cancer Res 2022;82(12_Suppl):Abstract nr CT511). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07026279 | Phase Ib/II | AMP945 | A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer | Recruiting | AUS | 0 |
| NCT05355298 | Phase Ib/II | AMP945 | AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer | Active, not recruiting | AUS | 1 |